文献
(201～300)201. Pfeffer MA, Braunwald E, Moyé LA, et al. SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-
677. PMID: 1386652
202. Køber L, Torp-Pedersen C, Carlsen JE, et al. Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-
converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;
333: 1670-1676. PMID: 7477219
203. Abdulla J, Barlera S, Latini R, et al. A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes
and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007; 9:
129-135. PMID: 16829187
204. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN
randomised trial. Lancet 2001; 357: 1385-1390. PMID: 11356434
205. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart
disease. J Card Fail 1997; 3: 249-254. PMID: 9547437
206. Scirica BM, Morrow DA, Cannon CP, et al. PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for
heart failure after an acute coronary syndrome in the PROVE ITTIMI 22 study. J Am Coll Cardiol 2006; 47: 2326-2331. PMID:
207. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a
comparative meta-analysis of randomised controlled trials. Heart 2007; 93: 914- 921. PMID: 17277349
208. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;
348: 1309-1321. PMID: 12668699
209. Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild
symptoms. N Engl J Med 2011; 364: 11-21. PMID: 21073363
210. Montalescot G, Pitt B, Lopez de Sa E, et al. REMINDER Investigators. Early eplerenone treatment in patients with acute ST-elevation
myocardial infarction without heart failure: the Randomized Double- Blind Reminder Study. Eur Heart J 2014; 35: 2295-2302. PMID:
211. 日本循環器学会．心筋梗塞二次予防に関するガイドライン（2011 年改訂版）．
212. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality
and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial
Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360: 752-760. PMID: 12241832
213. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both
in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. PMID:
214. Horinaka S, Yabe A, Yagi H, et al. JCAD Study Investigators. Effects of nicorandil on cardiovascular events in patients with coronary artery
disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74: 503-509. PMID: 20081320
215. Hochman JS, Lamas GA, Buller CE, et al. Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after
myocardial infarction. N Engl J Med 2006; 355: 2395-2407. PMID: 17105759
216. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313. PMID: 12151467
217. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;
27: 1879-1884. PMID: 15277411
218. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men--morbidity, risk factors and prognosis. J
Intern Med 2001; 249: 253-261. PMID: 11285045
219. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary disease. Circulation 2004; 110:
1424-1430. PMID: 15353499
220. 日本糖尿病学会．糖尿病治療ガイド2016-2017．文光堂 2016.
221. Pandey A, Garg S, Khunger M, et al. Dose-Response Relationship Between Physical Activity and Risk of Heart Failure: A Meta-Analysis.
Circulation 2015; 132: 1786-1794. PMID: 26438781
222. Echouffo-Tcheugui JB, Butler J, Yancy CW, et al. Association of Physical Activity or Fitness With Incident Heart Failure: A Systematic
Review and Meta-Analysis. Circ Heart Fail 2015; 8: 853-861. PMID: 26175539
223. Aune D, Sen A, Norat T, et al. Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality: A Systematic Review and
Dose-Response Meta-Analysis of Prospective Studies. Circulation2016; 133: 639-649. PMID: 26746176
224. Pandey A, LaMonte M, Klein L, et al. Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. J Am Coll
Cardiol 2017; 69: 1129-1142. PMID: 28254175
225. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality
in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128. PMID: 26378978
226. Fitchett D, Zinman B, Wanner C, et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients
with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526-1534.
PMID: 26819227
227. Fitchett D, Butler J, van de Borne P, et al. EMPA-REG OUTCOME® trial investigators. Effects of empagliflozin on risk for cardiovascular
death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J 2018;
39: 363-370. PMID: 29020355
228. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in
Type 2 Diabetes. N Engl J Med 2017; 377: 644-657. PMID:28605608
229. Kosiborod M, Cavender MA, Fu AZ, et al. CVD-REAL Investigators and Study Group. Lower Risk of Heart Failure and Death in Patients
Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative
Effectiveness of Cardiovascular Outcomes in New Users of Sodium- Glucose Cotransporter-2 Inhibitors). Circulation 2017; 136: 249-
259. PMID: 28522450
230. Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following
initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational
observational analysis. Lancet Diabetes Endocrinol 2017; 5: 709-717. PMID: 28781064
231. Suskin N, Sheth T, Negassa A, et al. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular
dysfunction. J Am Coll Cardiol 2001; 37: 1677-1682. PMID:11345383
232. Dorans KS, Mostofsky E, Levitan EB, et al. Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish
men. Circ Heart Fail 2015; 8: 422-427. PMID: 25872788
233. Gonçalves A, Claggett B, Jhund PS, et al. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study.
Eur Heart J 2015; 36: 939-945. PMID: 25602025
234. Gémes K, Janszky I, Ahnve S, et al. Light-to-moderate drinking and incident heart failure--the Norwegian HUNT study. Int J Cardiol
2016; 203: 553-560. PMID: 26569362
235. Tsuchihashi M, Tsutsui H, Kodama K, et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive
heart failure. Am Heart J 2001; 142: E7. PMID: 11579371
236. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North
Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435. PMID: 2883575
237. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left
ventricular ejection fractions. N Engl J Med 1992; 327: 685-691. PMID: 1463530
238. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
N Engl J Med 1991; 325: 293-302. PMID: 2057034
239. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic
dysfunction: a follow-up study. Lancet 2003; 361: 1843-1848. PMID: 12788569
240. Packer M, Poole-Wilson PA, Armstrong PW, et al. ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-
converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318. PMID:
241. Matsumori A. Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators. Efficacy and safety of
oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003; 5: 669-677. PMID: 14607207
242. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart
failure and reduced left-ventricular systolic function intolerant to angiotensin- converting-enzyme inhibitors: the CHARM-Alternative trial.
Lancet 2003; 362: 772-776. PMID: 13678870
243. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:
randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587. PMID: 10821361
244. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in
chronic heart failure. N Engl J Med 2001; 345: 1667-1675. PMID:11759645
245. McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart
failure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-Added trial. Lancet
2003; 362: 767-771. PMID: 13678869
246. Sakata Y, Shiba N, Takahashi J, et al. SUPPORT Trial Investigators. Clinical impacts of additive use of olmesartan in hypertensive patients
with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure
using olmesartan (SUPPORT) trial. Eur Heart J 2015; 36: 915- 923. PMID: 25637937
247. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717. PMID: 10471456
247a.Tsutsui H, Ito H, Kitakaze M, et al. J-EMPHASIS-HF Study Group. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the
Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circ J 2018; 82: 148-158. PMID:
248. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N
Engl J Med 2004; 351: 543-551. PMID: 15295047
249. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-
8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J
2013; 34: 2453-2463. PMID: 23713082
250. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:
9-13. PMID: 10023943
251. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/ XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF) Lancet 1999; 353: 2001-2007. PMID: 10376614
252. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658. PMID: 11386263
253. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and
metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised
controlled trial. Lancet 2003; 362: 7-13. PMID: 12853193
254. Hori M, Sasayama S, Kitabatake A, et al. MUCHA Investigators. Low-dose carvedilol improves left ventricular function and reduces
cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment
(MUCHA) trial. Am Heart J 2004; 147: 324-330. PMID: 14760332
255. Okamoto H, Hori M, Matsuzaki M, et al. J-CHF Investigators. Minimal dose for effective clinical outcome and predictive factors for
responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. Int J Cardiol 2013; 164: 238-244. PMID: 23245621
256. Böhm M, Swedberg K, Komajda M, et al. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association
between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894. PMID: 20801495
257. Tsuchihashi-Makaya M, Kinugawa S, Yokoshiki H, et al. JCARECARD Investigators. Beta-blocker use at discharge in patients hospitalized
for heart failure is associated with improved survival. Circ J 2010; 74: 1364-1371. PMID: 20501958
258. Yoshizawa A, Yoshikawa T, Nakamura I, et al. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for
congestive heart failure. J Card Fail 2004; 10: 310-315. PMID: 15309697
259. Hori M, Nagai R, Izumi T, et al. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic
heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II
(MAIN-CHF II) study. Heart Vessels 2014; 29: 238-247. PMID: 23559359
260. Gattis WA, O’Connor CM, Gallup DS, et al. IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients
hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol
Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43: 1534-1541. PMID: 15120808
261. Metra M, Nodari S, D’Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart
failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am
Coll Cardiol 2002; 40: 1248-1258. PMID: 12383572
262. Fonarow GC, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or
withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;
52: 190-199. PMID: 18617067
263. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac
function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006; 103: 11288-11293. PMID: 16844790
264. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.
Nat Med 2008; 14: 510-517. PMID: 18425130
265. Kotecha D, Holmes J, Krum H, et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart
failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235-2243. PMID: 25193873
266. Nielsen PB, Larsen TB, Gorst-Rasmussen A, et al. β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association
With Mortality in a Nationwide Cohort Study. Circ Heart Fail 2016; 9: e002597. PMID: 26823497
267. Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting
Atrial Fibrillation: An AF-CHF Substudy. JACC Heart Fail 2017; 5: 99-106. PMID: 28089316
268. Kotecha D, Flather MD, Altman DG, et al. Beta-Blockers in Heart Failure Collaborative Group. Heart Rate and Rhythm and the Benefit
of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol 2017; 69: 2885-2896. PMID: 28467883
269. Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised
controlled trials. Int J Cardiol 2002; 82: 149-158. PMID: 11853901
270. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular
Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705-708. PMID: 12932605
271. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational
study using propensity score methods. Eur Heart J 2006; 27: 1431- 1439. PMID: 16709595
272. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97:
1759-1764. PMID: 16765130
273. Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail
2006; 12: 327-332. PMID: 16762792
274. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart
J 1987; 57: 17-22. PMID: 3541995
275. Masuyama T, Tsujino T, Origasa H, et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure.
Circ J 2012; 76: 833-842. PMID: 22451450
276. Gheorghiade M, Konstam MA, Burnett JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan
(EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure:
the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.PMID: 17384438
277. Konstam MA, Gheorghiade M, Burnett JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan
(EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
JAMA 2007; 297: 1319-1331. PMID: 17384437
278. Shirakabe A, Hata N, Yamamoto M, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and
improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 2014; 78: 911-921.
PMID: 24553192
279. Jujo K, Saito K, Ishida I, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute
heart failure. ESC Heart Fail 2016; 3: 177-188. PMID: 27818782
280. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of lowdose amiodarone in severe congestive heart failure. Grupo de Estudio
de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Lancet 1994; 344: 493-498. PMID: 7914611
281. Massie BM, Fisher SG, Radford M, et al. CHF-STAT Investigators. Effect of amiodarone on clinical status and left ventricular function in
patients with congestive heart failure. Circulation 1996; 93: 2128- 2134. PMID: 8925581
282. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in
congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424. PMID:
283. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237. PMID: 15659722
284. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans
Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552. PMID: 3520315
285. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive
heart failure. N Engl J Med 1991; 325: 303-310. PMID: 2057035
286. Taylor AL, Ziesche S, Yancy C, et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and
hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049-2057. PMID: 15533851
287. Packer M, O’Connor CM, Ghali JK, et al. Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine
on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114. PMID: 8813041
288. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:
525-533. PMID: 9036306
289. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA
2003; 289: 871-878. PMID: 12588271
290. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;
347: 1403-1411. PMID: 12409542
291. Washam JB, Stevens SR, Lokhnygina Y, et al. ROCKET AF Steering Committee and Investigators. Digoxin use in patients with atrial
fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet
2015; 385: 2363-2370. PMID: 25749644
292. Packer M, Carver JR, Rodeheffer RJ, et al. PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic
heart failure. N Engl J Med 1991; 325: 1468-1475. PMID: 1944425
293. Cohn JN, Goldstein SO, Greenberg BH, et al. Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone
among patients with severe heart failure. N Engl J Med 1998; 339: 1810-1816. PMID: 9854116
294. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive
heart failure. Heart Vessels 1994; 9: 113-120. PMID: 8056717
295. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the
Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-231. PMID: 8868980
296. Yoshikawa T, Baba A, Suzuki M, et al. Keio Interhospital Cardiology Study (KICS) Group. Effectiveness of carvedilol alone versus carvedilol
+ pimobendan for severe congestive heart failure. Am J Cardiol 2000; 85: 1495-1497. PMID: 10856401
297. EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate
chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 2002; 66: 149-157. PMID:11999639
298. McMurray JJ, Krum H, Abraham WT, et al. ATMOSPHERE Committees Investigators. Aliskiren, Enalapril, or Aliskiren and Enalapril
in Heart Failure. N Engl J Med 2016; 374: 1521-1532. PMID: 27043774
299. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico). Dietary supplementation
with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:
447-455. PMID: 10465168
300. Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart
failure (the GISSI-HF trial): a randomised, double-blind, placebo- controlled trial. Lancet 2008; 372: 1223-1230. PMID: 18757090
急性･慢性心不全診療ガイドライン（2017年改訂版）
Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure
（JCS 2017/JHFS 2017）